Overview

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Status:
Terminated

Trial end date:
2018-03-21

Target enrollment:

Participant gender:

Summary

This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa for the treatment of anemia in subjects with Dialysis-dependent Chronic Kidney Disease (DD-CKD) who are hyporesponsive to erythropoiesis stimulating agents (ESAs.)

Phase:

Phase 2

Details

Lead Sponsor:

Akebia Therapeutics

Treatments:

Epoetin Alfa
Hematinics